Michael Weisser
CEO
AIM Gmbh (Assessment-in-Medicine)
The principles of market access differ greatly from traditional 4 P product price place promotion Marketing. The winning combination of clear demonstration of Patient, Provider Payer and Product benefits (Optimizing price but maximising the availability to patients who need the technology most) to HTA’s leads to faster adoption meaning patients receive great technologies sooner.
Michael Branagan-Harris
CEO
Device Access UK
Richard Charter
Director Value-Based Healthcare
ValueConnected
While evidence requirements have changed under the new European framework for CE arking, the movement towards pan-European Health Technology Assessment also has gained traction, prompting greater conformity of HTA evidence requirements and "transplantation" of evidence reviews across geographies within the European Union. Companies can expect CE Mark requirements to be more aligned with the demands of HTA bodies for reimbursement, but the challenges for medical device firms are greater, as local HTA bodies may be commissioned to implement assessments that have a pan-European impact.
Stephen Hull
Principal and Founder
Hull Associates, USA